source
- Viatris to acquire Pacira BioSciences for $1.65 billion, adding two non-opioid pain drugsViatris announced Thursday it will purchase Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share, a 45% premium to the prior close. The acquisition gives Viatris control of Pacira…
- Caribou Biosciences explores strategic alternatives, drawing interest as a reverse-merger candidateCaribou Biosciences, the cell‑therapy company co‑founded by CRISPR pioneer Jennifer Doudna, announced it is evaluating strategic alternatives as it faces a difficult financing environment. The com…